Introduction
Granulocyte-colony stimulating factor (G-CSF) is an important cytokine in regulating immune defences against pathogenic microorganisms.
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During hematopoiesis, G-CSF stimulates BM stem cells to differentiate into myeloid cells, including granulocytes. 2 Nowadays, G-CSF is widely used in the treatment of patients with chemotherapy-induced neutropenia and in preparation of hematopoietic stem cells (HSCs) mobilized for transplantation before initiation of myeloablative chemotherapy. 3 In addition, after HSC donors have received G-CSF for five days, their T cells produce less IFN-g and more IL-4 compared with pretreatment levels, suggesting that G-CSF therapy might be associated with a lower risk of acute GVHD. 4 Human natural killer (NK, CD56 þ CD3 À ) cells are critical for cytotoxic host defense against infected cells and tumors, including Fas-Fas ligand-triggered apoptosis and toxic granule exocytosis, in both innate and adaptive immunity. 5, 6 Our previous study demonstrated that the cytotoxicity of CD56 þ CD3 À NK cells isolated from human peripheral blood was markedly increased after treatment with SCF, IL-3 and granulocyte/macrophage-CSF; in contrast, G-CSF attenuated NK cell-mediated cytotoxicity. 7 Moreover, G-CSF-mediated downregulation of NK cell activity may be associated with several cytotoxicity-related protein expressions, such as triosephosphate isomerase (TPI), calreticulin and ubiquitin-conjugating enzyme E2H. 7 NK cell activity is also involved in a variety of pathologic conditions, such as autoimmune diseases and transplant rejection. 8 In particular, for hematopoietic SCT (HSCT) of leukemia patients, NK cells have a critical role in regulating immune responses, including GVHD and GVL effects. 8 HSCT, whether hematopoietic stem cells derived from the BM, cord blood or peripheral blood, is a medical strategy used for select patients with blood-and BMrelated diseases and certain types of cancers. 9 Although autologous HSCT is not suitable for most patients, various types of allogenic (allo)-HSCT, including unrelated donorand haploidentical allo-HSCT, appear to improve chances for successful treatment compared with no transplantation. 10 It has been reported that the higher CD34 þ cell dose used in unrelated donor allo-HSCT is associated with reduced risk for relapse, which may be immune-mediated through NK cell recovery. 11, 12 In contrast, other researchers have reported that alloreactive NK cells triggered by allo-HSCT may increase the rate of infection and increase early post-transplantation mortality among patients with AML. 13 G-CSF increases the alloAg-presenting capability of immune accessory cells. 7, 14 However, in one study it diminished the cytotoxic ability of NK cells, 15 and in another (with 104 healthy donors), it decreased immune function in G-CSF-mobilized PBSCs. 16 Our previous study isolated CD56 þ CD3 À NK cells from peripheral blood and demonstrated that G-CSF was effective at inhibiting NK cell activity through the regulation of several cytotoxicityrelated proteins. 7 Because of the controversy regarding NK cell activity in the setting of G-CSF-mobilized allo-HSCT, clarification of the role of G-CSF in regulating NK cell activity is necessary. The present study assayed NK cell activity in both G-CSF-treated NK-92MI cell lines and in NK cells isolated from the peripheral blood of donors treated with G-CSF before allo-HSCT. Possible signaling pathways, including phosphatidylinositol 3-kinase (PI3K), Akt, mammalian target of rapamycin (mTOR), mitogenactivated protein kinases (MAPKs), and finally, the expression of cytotoxicity-related genes were also assessed.
Subjects and methods

Subjects and NK cell isolation
To assess G-CSF effect in donors for allo-HSCT, 32 healthy volunteers (20-40 years old) received high-dose G-CSF (Filgrastim, 10 mg/kg once daily i.v.; Kirin Brewery, Tokyo, Japan) injections for five consecutive days, after which blood samples were freshly collected for NK cell isolation and ELISA of plasma levels. Another group of blood samples from 30 volunteer donors (20-40 years old) who did not receive G-CSF injections were also collected to provide the normal controls. The research on human subjects was approved before implementation by the relevant Institutional Review Board of Buddhist Dalin Tzu Chi General Hospital, Taiwan (No. B09604006). All participants provided written informed consent at enrollment. Donors had peripheral blood cell counts (with differential by type) measured at baseline and after the last injection of G-CSF. For NK cell isolation, human PBMCs were separated on a density gradient (FicollHypaque, 1.077 g/mL, Pharmacia Fine Chemicals, Uppsala, Sweden), followed by centrifugation at 2000 r.p.m. for 15 min. Adhesive monocytes were removed by adhesion to a plate for 90 min and non-adhesive lymphocytes were collected for NK cell isolation using a MACS device and NK Cell Isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD56 þ CD3 À NK cells, with a purity of more than 80% as determined by flow cytometry, were cultured in RPMI1640 medium supplemented with 2 g/L sodium bicarbonate, 25 mM HEPES, 10% heat-inactivated FBS and 2 mM L-glutamine and maintained at 37 1C in a humidified 5% CO 2 incubator.
Cell lines and cell culture
Human NK cell line NK-92MI and human chronic myeloid leukemia K562 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The NK-92MI cell line was derived from NK-92 cells with the transfection of human IL-2 cDNA, which was isolated from a male patient with malignant non-Hodgkin's lymphoma. NK-92MI cells were maintained in a-MEM medium (Gibco, Carlsbad, CA, USA) supplemented with 12.5% FBS(Gibco), 12.5% horse serum, and 2 mM L-glutamine (Sigma, St Louis, MO, USA). For in vitro cytotoxicity assay, 1 Â 10 6 NK-92MI cells per mL were pretreated with recombinant human G-CSF (2 and 4 ng/mL; CytoLab Ltd, Rehovot, Israel) and/or inhibitors, such as 10 mM PD98059 (BioSource, Camarillo, CA, USA) or 100 nM wortmannin (Cell Signaling, Boston, MA, USA), for 16 h and then adjusted for the following cytotoxicity method. K562 cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS and 2 mM Lglutamine, and maintained in a 37 1C incubator for use in NK cell cytotoxicity assays.
Cytotoxicity assay NK cell cytotoxicity against K562 target cells was assayed in triplicate by the lactate dehydrogenase release method. In brief, NK cells isolated from normal controls and G-CSF-mobilized donors or NK-92MI cells with G-CSF (0-4 ng/mL) and/or wortmannin (100 nM, PI3K inhibitor, Cell signaling) treatment for 16 h were collected and co-cultured with K562 cells in a 96-well plate at effector to target cell ratios of 5:1, 10:1 or 20:1. After 4 h, each plate was centrifuged at 250 g for 5 min, after which the supernatant was transferred to a new plate and adjusted for lactate dehydrogenase measurement using the CytoTox 96 non-radioactive cytotoxicity assay kit (Promega, Madison, WI, USA). According to the manufacturer's recommendations, absorbance at 490 nm was recorded for each reaction, from which the percentage of cells killed by cytotoxic activity (%) was calculated.
To assess the effect of G-CSF on NK cell viability and apoptosis induction, the numbers of NK cell and apoptotic percentage with and without G-CSF treatment were measured using the Trypan blue dye exclusion test and flow cytometric assay, respectively.
ELISA assay of plasma TRAIL ELISA kits (R&D Systems, Minneapolis, MN, USA) were used to determine human TRAIL/TNFSF10 plasma levels in both normal controls and donors treated with G-CSF before HSCT. Assay was performed according to the manufacturer's protocol.
Western blot analysis of PI3K, AKT, mTOR and MAPKs NK cells isolated from normal controls and donors treated with G-CSF and NK-92MI cells after 16-h G-CSF (0, 2 and 4 ng/mL) treatment were collected. Total proteins were extracted, and individual protein concentrations were quantified by a bicinchoninic acid protein assay kit (Sigma). The same amount of protein (20 mg per well) was disrupted with 2 Â concentrated electrophoresis sample buffer (1 M Tris, pH 6.8, 5% SDS, 40% glycerol, 0.005% bromophenol blue and 8% b-mercaptoethanol) and subjected to gel electrophoresis using 10% SDS-polyacrylamide gels. Afterward, the protein gel was transferred to a polyvinylidene difluoride membrane, the membrane was blotted with antibodies (such as anti-PI3K, Akt, mTOR, MAPKs and glyceraldehyde-3-phosphate dehydrogenase; Cell Signaling Technology, Boston, MA, USA) at a dilution of 1:1000, and protein bands were detected using horseradish peroxidase-conjugated anti-mouse IgG (1:10 000-fold dilution) followed by enhanced chemiluminescence. Relative protein levels were determined by densitometry using ImageJ software (Version 1.36b, NIH, Bethesda, MD, USA), and the relative values were normalized to the internal glyceraldehyde-3-phosphate dehydrogenase control.
Electrophoretic mobility shift assay of NF-kB activity NK-92MI cells with or without G-CSF (2 and 4 ng/mL) treatment for 24 h were collected, and nuclear proteins were extracted. To prepare nuclear proteins, the nuclei were first separated from the cytosol by the nuclear extraction buffer (500 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 20% Glycerol, 0.1% Triton X-100, and 20 mM Hepes, pH 7.4). The nuclei were then resuspended in lysis buffer (150 mM NaCl, 0.1% SDS, 1% Triton X-100, and 100 mM Tris, pH 8.0) and centrifuged at 400 g for 10 min. The nuclear proteins were collected and stored at À80 1C. Electrophoretic mobility shift assay was performed using 20 mg nuclear extract per reaction, 50 ng/mL poly (dI/dC) and 20 fmol biotin 3 0 end-labeled target DNA: sense 5 0 -TG AGGGGACTTTCCCAGG-3 0 and anti-sense 5 0 -CCTGG GAAAGTCCCCTCA-3 0 . The LightShift Chemiluminescent assay kit was purchased from Pierce (Rockford, IL, USA), and procedures were performed according to the manufacturer's instructions.
Reverse transcription-PCR (RT-PCR) assay of cytotoxicity-related genes
Total RNA was isolated from NK-92MI cells using TRIzol reagent (Life Technologies, Gaithersburg, MD, USA), and then reverse-transcribed to cDNA by reaction in a PCR thermal cycler (Bio-Rad, Hercules, CA, USA) for 10 min at 25 1C, 70 min at 37 1C, 10 min at 72 1C, and stored at 4 1C. The cytotoxicity-related genes were amplified using specific primers (Mission Biotech, Taipei, Taiwan, PRC), and PCR thermal cycle profiles are listed in Table 1 . PCR products were assayed by electrophoresis in a 1% agarose gel in Tris-acetate/EDTA buffer and visualized by ethidium bromide (0.01%) staining. Glyceraldehyde-3-phosphate dehydrogenase was the housekeeping gene used for internal control.
Statistical analysis
All data were obtained from at least three independent experiments with results expressed as the mean±s.d. or s.e.m. Student's t-test or analysis of variance was applied to compare NK cell activity of G-CSF-treated group and untreated controls for both the in vitro and human studies. Differences were considered significant at Po0.05.
Results
NK cell-mediated cytotoxicity and plasma levels of TRAIL in G-CSF-mobilized donors Cytotoxic effect was observed for NK cells isolated from 32 G-CSF-mobilized donors as compared with 30 untreated normal control donors (Figure 1a ). Cells from both male and female donors had comparable results after G-CSF injection. In addition, TRAIL is produced by NK cells for cytotoxicity. Figure 1b shows that the ELISA assay of plasma TRAIL levels in G-CSF-mobilized donors were slightly decreased, but the change was not statistically significant (P ¼ 0.058). Figure 1c indicates that the reduced NK cell-mediated cytotoxicity in G-CSF-mobilized donors returned to baseline after 1-2 years of G-CSF injection. Moreover, Table 2 lists change by cell type in donor blood obtained before and after G-CSF treatment. After G-CSF injection for five consecutive days, numbers of total WBCs, CD34 þ cells, neutrophils (band) and other blasts were markedly increased when compared with counts obtained from the same individuals before G-CSF injection. This suggests that G-CSF injection might regulate the immunological network, including activation of CD34 þ cells, granulocytes and lymphocytes. However, changes of blood cells reversed roughly within 1 year after G-CSF injection ( Table 2) . Figure 2a demonstrates that expression of PI3K, both p85a-and b-chains, was downregulated in NK cells isolated from G-CSF-mobilized donors. In addition, a PI3K downstream molecule phosphorylated (p)-Akt showed decreased expression in NK cells isolated from G- 
Expression of PI3K, AKT and mTOR in normal control and G-CSF-mobilized donors
CSF-mobilized donors; however, there was no change in p-mTOR expression in the same treatment (Figure 2b) . The results indicated that NK cell-mediated cytotoxicity may be regulated through PI3K/Akt, but not mTOR.
Cytotoxic effect of G-CSF in NK-92MI cells
Lactate dehydrogenase release due to NK cell-mediated cytotoxicity against K562 cells was significantly decreased by G-CSF treatment (Figure 3a) . The Trypan blue dye exclusion test showed that NK-92MI cells treated with G-CSF (0, 2 or 4 ng/mL) had no change in cell viability (Figure 3b ). Flow cytometric assay of G-CSF-NK cells showed no increase in the percentage of sub-G1 phase, indicating that there were no apoptosis induced by G-CSF (data not shown). To provide further evidence for the survival of NK-92MI cells by G-CSF treatment, we examined the DNA-binding activity of nuclear NF-kB in response to G-CSF treatment. As demonstrated in Figures 3c and d , G-CSF decreased cytotoxicity without affecting NF-kB expression and NF-kB activity of NK cells.
The role of PI3K in G-CSF-treated NK-92MI cells Figure 4a demonstrates that expression of PI3K was also downregulated in G-CSF-treated NK-92MI cells. The treatment with the PI3K inhibitor wortmannin not only decreased NK cell-mediated cytotoxicity, but also enhanced the downregulating effect of G-CSF in NK-92MI cells (Figure 4b ). The results indicate that G-CSF-mediated cytotoxicity of NK cells may have a high correlation with PI3K signaling regulation. Figure 5a shows that p-ERK expression of NK-92MI cells treated with G-CSF (0-4 ng/mL) was downregulated, and NF-kB-DNA-binding activity by electrophoretic mobility shift assay analysis. The analysis was performed on three independent experiments with similar results and all data were expressed as mean ± s.e. *Po0.05 was considered significantly different from the control data. All results were expressed as mean ± s.d.
Expression of MAPKs in NK-92MI cells with and without G-CSF treatment
there was no change in JNK and P38. Pretreatment of ERK inhibitor PD98059 enhanced the decrease of cytotoxicity in G-CSF-treated NK-92MI cells (Figure 5b ), implying that G-CSF-induced downregulation of NK cell-mediated cytotoxicity might be regulated through the decreased expression of p-ERK.
Expression of cytotoxicity-related genes in NK-92MI cells with and without G-CSF treatment
Our previous study demonstrated a decrease in NK cellmediated cytotoxicity by G-CSF possibly by regulation through several cytotoxicity-related proteins. 8 Further analysis of gene expression in NK cells by RT-PCR demonstrated that the TPI gene, but neither ubiquitin nor calreticulin genes, was downregulated by G-CSF treatment (Figure 6a) . Table 1 lists the primers used in this study. Figure 6b shows results for NK-92MI cells where treatment with wortmannin enhanced the decrease in TPI mRNA levels. However, ERK inhibitor PD98059 did not influence the change of TPI level by G-CSF treatment, suggesting that G-CSF acts on pathways other than ERK. The results indicated that NK cell-mediated cytotoxicity might be downregulated by G-CSF via decreased expression of the PI3K signaling molecule and TPI gene.
Discussion
Regulation of NK-cell stimulatory and inhibitory receptors that interact with MHC class I and class I-like molecules on target cells causes activation and inhibition of NK cellmediated cytotoxicity. 17 Schlahsa et al. 18 indicated that the expression of the activating receptors (NKp46 and NKG2D) and inhibitory receptors (KIR2DL1 and KIR2DL2) decreased about 40-64% and 46% (each), respectively, by G-CSF treatment. Moreover, the cell line we used in this study, NK-92MI cells, lacks most of the inhibitory receptors, 19 but the direct inhibitory effect of G-CSF on NK cell activity has a similar response in G-CSFtreated NK-92MI cells (Figure 3a from G-CSF-mobilized stem cell donors of both sexes (Figure 1a) . We suggest that G-CSF-decreased NK cell cytotoxicity may also be mediated through other receptors, such as cytokine receptors. Cytokine receptors are widely expressed in various cells, which can receive cytokine (such as G-CSF) stimulation and initiate certain cellular responses. 20 In Figure 1b , the ELISA assays of plasma TRAIL levels in G-CSF-mobilized donors were slightly decreased, but the change was not statistically significant (P ¼ 0.058). Although the level of TRAIL did not change significantly, the cytotoxicity of NK cells was decreased by G-CSF in this study and in our previous study. 7 One possibility is TRAIL production in other immune cells, such as CTLs, provokes cytotoxicity to the target. One study indicated that multipeg-G-CSF enhanced CTL function and maximized GVL effects; 21 therefore, G-CSF effect on other cells may influence the plasma levels of TRAIL in this study. Furthermore, the downregulation of NK cytotoxic activity by G-CSF is not via the decrease of NK cell number and induction of apoptosis (Figure 3b ). Because NF-kB is a central transcription factor for regulating anti-apoptosis and cell survival, 22 this study also examined DNA-binding activity of nuclear NF-kB by using the electrophoretic mobility shift assay method. Our results showed that G-CSF did not change NF-kB expression and NF-kB transactivity in NK-92MI cells (Figures 3c and d) , indicating that G-CSF decreased NK cell activity without affecting viability and NF-kB activity of NK cells.
G-CSF is a hematopoietic growth factor commonly used in cancer patients who experience myelosuppression after radiotherapy or chemotherapy. 23 In HSCT donors, G-CSF induces rapid mobilization of stem cells, especially CD34 þ cells, to peripheral blood. 24 Our study also demonstrated that the numbers of total WBCs, CD34 þ cells, neutrophils (band) and other blasts were markedly increased after G-CSF injection for five consecutive days (Table 2) . Although G-CSF supports chemotherapy and has benefits in immuno-regulation, its long-term safety has not been evaluated. Hershman et al. 25 reported that use of G-CSF in patients with breast cancer was associated with a doubling in risk of subsequent AML or myelodysplastic syndrome. It has been suggested that the increased risk of leukemia might correlate with G-CSF-mediated downregulation of NK-and T-cell activities. 4, 7 Rondelli et al. 14 demonstrated that treating healthy donors with G-CSF (10 mg/kg/day, 5 days) for stem cell mobilization may prevent their Th1 cell alloresponses and decrease the percentage of CD56 þ NK cells among PBMCs. Therefore, use of G-CSF in cancer patients who will receive autologous HSCT should be cautious, especially in avoiding adversely influencing Tand NK-cell-mediated immunocompromise.
14 NK cells, like T cells, express killer cell Ig-like receptors that recognize different groups of human leukocyte Ag class I alleles and have a critical role in GVHD associated with clinical outcome in haploidentical HSCT. 26 This study demonstrated that cytotoxic activity of NK cells obtained from peripheral blood was decreased by G-CSF injection, suggesting that the HSCT recipients may have a lower risk of acute GVHD. Additionally, our results also indicated that NK cells recover cytotoxicity after removal of G-CSF stimulation (Figure 1c) . Although the time point is not clear in this study, the finding suggests that G-CSFmobilized donors probably recover NK cell activity after transplantation and that recovered NK cells may provide later-phase cytotoxic GVL effects in this group of recipients. Further investigation of precise time points will be redesigned and analyzed in our ongoing work.
Articles have reported that PI3K links NKG2D-activated signaling pathway in NK cells with cellular adhesion, polarity, development, and cytokine and granule secretion, 27, 28 implying that inhibition of the PI3K/Akt The relative values were normalized to the internal glyceraldehyde-3-phosphate dehydrogenase control and were calculated from at least three independent experiments. All results were expressed as mean±s.d. *Po0.05 was considered significantly different from the control data.
pathway could inhibit the cytotoxic effect of NK cells. This study demonstrated that G-CSF downregulation of NK cell cytotoxicity was accompanied by decreased expression of PI3K in donor NK cells (Figure 2a ) and NK-92MI cell line (Figure 4a ). PI3K inhibitor wortmannin alone and combined with G-CSF significantly decreased the cytotoxicity of NK-92MI cells (Figure 4b ), suggesting that G-CSF, like wortmannin, decreased NK cell-mediated cytotoxicity, probably through the downregulation of PI3K signaling. One article indicated that sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells and induces signaling of PI3K and protein kinase B/Akt. 29 IL-2-stimulated NK-92 cells induce human telomerase reverse transcriptase activation involving regulation through PI3K/Akt, Hsp90, mTOR and S6K molecules. 30 However, mTOR inhibitor rapamycin blocks progression of the cell cycle in NK cells, but seems not to influence NK cell cytotoxicity. 31, 32 Our results also showed that NK cells isolated from G-CSFmobilized donors had markedly decreased expression of PI3K and p-Akt, but no change of mTOR (Figure 2) , implying that NK cell-mediated cytotoxicity may be regulated through the signaling of PI3K and Akt.
The PI3K/Akt pathway may also be required for regulation of MAPK signaling in NK cells. Wiseman et al. 33 demonstrated that downstream of PI3K, ERK1/2 is activated in PI3K-dependent fashion and is an essential element in the killing of microorganisms by NK cells. This study further investigated downstream regulation of MAPKs and found that p-ERK2 was downregulated in G-CSF-treated NK-92MI cells ( Figure 5a) ; furthermore, the ERK inhibitor PD98059 enhanced NK cell-mediated cytotoxicity that had been decreased by G-CSF ( Figure 5b) ; it is therefore thought that NK cell activity may also be regulated through ERK/MAPK signaling.
Our previous investigation with primary NK cells demonstrated that G-CSF-downregulated NK cell activity may be associated with expression of several cytotoxicityrelated proteins, such as TPI, calreticulin and ubiquitinconjugating enzyme E2H. 7 The current study confirmed expression of mRNA and showed a significant decrease of TPI in G-CSF-treated NK-92MI cells (Figure 6a ). The glycolysis protein TPI regulates cellular bioenergetic processes and initiates signal transduction, like PI3K and MEK1/2 signalings. 34, 35 This study also assessed the effect of the PI3K inhibitor wortmannin and ERK inhibitor PD98059 on TPI gene expression in NK-92MI cells with and without subsequent G-CSF treatment (Figure 6b ). The data indicated that PD98059 did not influence the change of TPI level by G-CSF treatment, whereas wortmannin significantly decreases TPI expression in NK-92MI cells. It was suggested that NK cell-mediated cytotoxicity might be downregulated by G-CSF through the PI3K/Akt and ERK/MAPK signaling molecules, and the PI3K/Akt signaling then decreased expression of cytotoxicity-related molecules, TPI, while the ERK/MAPK signaling may be involved in regulation of other genes, such as cellular adhesion, polarity, development, cytokine production and granule secretion. 27, 28 Recently, clinicians have begun to use new agents such as plerixafor (AMD3100) to optimize the mobilization of HSC before transplantation for treatment of hematologic diseases and inborn errors of metabolism. 23, 36 Our results may provide additional important information regarding regulation of NK cell activity for developers of potential drugs for advanced stem cell mobilization in HSCT. In conclusion, the present study, which used both donor NK cells and an NK cell line, demonstrated that G-CSF, a growth factor commonly used to mobilize stem cells in transplantation, may impair NK cell-mediated cytotoxicity through signaling regulation of PI3K/Akt and ERK/ MAPK, and then decrease cytotoxicity-related gene expression. Additionally, the effect of G-CSF on NK cells is transient, and NK cell activity may return to baseline after clearance of G-CSF, suggesting that G-CSF may have benefits for allo-HSCT recipients in both prevention of acute GVHD and promotion of late-phase GVL effects.
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